iBio, Inc. (NYSEA: IBIO), a trailblazer in the biotechnology sector, has made significant strides in expanding its AI-powered technology stack with the introduction of ShieldTx, a groundbreaking antibody masking technology.
Announced on November 1, 2023, this patent-pending innovation is poised to transform the landscape of targeted antibody delivery, offering a beacon of hope for patients suffering from various forms of solid tumours, including ovarian, lung, and pancreatic cancers.
A Leap Forward in Drug Discovery
At the heart of iBio’s technological advancement is ShieldTx, seamlessly integrated into the company’s Drug Discovery Platform. This revolutionary technology is designed to ensure the specific, highly targeted delivery of antibodies to diseased tissue, sparing healthy tissue from potential harm.
By amalgamating antibody engineering and masking into a singular, accelerated process, ShieldTx stands to address the quintessential challenges of complex targets, safety, and developability that have long plagued next-generation antibody discovery and development.
Read More: Can This Data Analytics Company Compete With The Big Boys?
Tackling the Challenge of Specificity in Therapy
The genesis of ShieldTx was marked by its application in developing masks for iBio’s MUC16-targeted bispecific antibody candidates. These candidates were initially crafted using iBio’s proprietary Epitope Steering and EngageTx™ AI Platforms.
The innovation behind ShieldTx revolves around the concept of antibody masking—a technique that deactivates antibodies until they encounter a specific enzyme unique to the target diseased tissue.
Upon interaction, the mask is removed, activating the antibody solely where it is needed, thereby enhancing therapeutic safety and reducing the risk of unwanted immune responses.
Redefining Traditional Masking Techniques
Traditionally, antibody masking has been fraught with complexity, necessitating the sequential optimization of both the antibody and its mask—a process that invariably extends development timelines and introduces additional risks.
iBio’s ShieldTx, however, innovates by fine-tuning the mask and antibody concurrently through the StableHu™ antibody optimizer, employing its mammalian display technology. This approach not only streamlines the development process but also elevates the probability of success in generating effective masked antibodies.
Also Read: Can This Data Analytics Company Compete With The Big Boys?
The Potential of ShieldTx Across Therapeutic Areas
The implications of ShieldTx’s successful application are vast and varied. While initially geared towards cancer therapeutics, the potential utility of this technology in autoimmune and inflammatory diseases remains an exciting frontier.
iBio plans to leverage ShieldTx to optimize its existing antibody candidates, notably the bispecific TROP-2 x CD3 molecules developed through its EngageTx antibody panel.
Driving Innovation in Antibody-Based Therapeutics
Underpinning iBio’s mission is the pursuit of unlocking new therapeutic avenues against challenging and complex targets.
“With 40% of approved antibodies targeting merely 10 entities, the imperative for innovation in therapeutic development against new targets is clear,” remarked Martin Brenner, DVM, Ph.D., iBio’s CEO and CSO.
iBio’s commitment to integrating cutting-edge technologies in machine learning, computational biology, and synthetic biology is evident in its rapid development of an integrated end-to-end platform.
ShieldTx, alongside the earlier introduction of EngageTx, epitomizes iBio’s dedication to crafting the next generation of antibody-based therapeutics.
As iBio continues to forge pathways in the biotechnological realm, ShieldTx stands as a testament to the company’s ingenuity and its unwavering commitment to enhancing the precision and safety of antibody therapies.
With the promise of delivering targeted treatments while minimizing off-tissue effects, ShieldTx heralds a new era in the quest for more effective and safer therapeutic options across a spectrum of diseases.
Read Next: FDA Greenlights Mesoblast’s Resubmission for Pediatric Graft-Versus-Host Disease Treatment
DISCLAIMER
You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Kevin is an experienced business development strategist and content writer specializing in finance and stock market topics. He has a proven track record of driving sales and enhancing communications for small businesses by blending academic knowledge with practical experience to create engaging and accurate content.
